Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 13/20 | 0.84 |
| ▸ | DRD1 | P21728 | 1/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.84 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23310424 | 1.00 | GNRHR (0.84) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL30882997 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL30882994 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL29887354 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL24040296 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL30883014 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL24040283 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL24040297 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL571416 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL30742606 | 0.97 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153802-A1 | A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153802-A1 | A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE | LPXN, GNRHR, CYP19A1 | GNRHR 2/4885DRD1 2759/4885OPRM1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.